TI-0093
/ Therorna
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
November 25, 2025
Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors
(clinicaltrials.gov)
- P1 | N=12 | Recruiting | Sponsor: Therorna | Enrolling by invitation ➔ Recruiting
Enrollment status • Cervical Cancer • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck
November 20, 2025
Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors
(clinicaltrials.gov)
- P1 | N=12 | Enrolling by invitation | Sponsor: Therorna | Not yet recruiting ➔ Enrolling by invitation
Enrollment open • Cervical Cancer • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck
July 25, 2025
Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors
(clinicaltrials.gov)
- P1 | N=12 | Not yet recruiting | Sponsor: Therorna
New P1 trial • Cervical Cancer • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck
1 to 3
Of
3
Go to page
1